The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.
 
Benjamin Miron
Employment - NovellusDx
Leadership - NovellusDx
Stock and Other Ownership Interests - Clovis Oncology; Guardant health
 
Elizabeth A. Handorf
Honoraria - NCCN/Pfizer
Research Funding - NCCN/Lilly (Inst); Pfizer (Inst); Pfizer (Inst)
 
Kevin Zarrabi
No Relationships to Disclose
 
Matthew R. Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - EMD Serono; Exelixis; Horizon Pharma; Janssen; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Horizon Pharma (Inst); Pfizer (Inst)
Other Relationship - Association of Community Cancer Centers (ACCC)
 
Pooja Ghatalia
No Relationships to Disclose
 
Fern Anari
No Relationships to Disclose
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Flatiron Health; Genentech/Roche; Infinity Pharmaceuticals; Janssen; MEI Pharma; Merck; Pfizer; Seattle Genetics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Daniel M. Geynisman
Employment - 2nd.MD
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Merck; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
Research Funding - Astellas Pharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Merck (Inst)